Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia
Xiaoyang Hua, … , Stephen Tilley, Stanley Perlman
Xiaoyang Hua, … , Stephen Tilley, Stanley Perlman
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e99025. https://doi.org/10.1172/jci.insight.99025.
View: Text | PDF
Research Article Immunology Virology

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia

  • Text
  • PDF
Abstract

The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.

Authors

Xiaoyang Hua, Rahul Vijay, Rudragouda Channappanavar, Jeremiah Athmer, David K. Meyerholz, Nitin Pagedar, Stephen Tilley, Stanley Perlman

×

Figure 8

T cell responses after SARS-CoV infection in mice with or without prior nasal-only MHV-1 inoculation.

Options: View larger image (or click on image) Download as PowerPoint
T cell responses after SARS-CoV infection in mice with or without prior ...
SARS-CoV–infected mice with or without prior nasal-only MHV-1 inoculation were analyzed for virus-specific T cell responses in the lungs. (A and B) Representative flow plots showing frequency of virus-specific CD8 (S366-specific) and CD4 (N353-specific) T cell responses on day 6 after infection with 104 PFU SARS-CoV. RP10 medium without specific peptide. (C and D) Summary data for frequency and total number of virus-specific T cells are shown in the bar graphs. *P < 0.05; **P < 0.01. n = 4 per group.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts